WO1997039771A1 - Heterologous boosting immunizations - Google Patents
Heterologous boosting immunizations Download PDFInfo
- Publication number
- WO1997039771A1 WO1997039771A1 PCT/US1997/006632 US9706632W WO9739771A1 WO 1997039771 A1 WO1997039771 A1 WO 1997039771A1 US 9706632 W US9706632 W US 9706632W WO 9739771 A1 WO9739771 A1 WO 9739771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- recombinant
- antigen
- gal
- tumor
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title claims description 53
- 238000002649 immunization Methods 0.000 title claims description 48
- 239000013598 vector Substances 0.000 claims abstract description 107
- 108091007433 antigens Proteins 0.000 claims abstract description 79
- 239000000427 antigen Substances 0.000 claims abstract description 77
- 102000036639 antigens Human genes 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 47
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 241000700618 Vaccinia virus Species 0.000 claims description 28
- 239000013603 viral vector Substances 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 17
- 241000700662 Fowlpox virus Species 0.000 claims description 14
- 230000003308 immunostimulating effect Effects 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 6
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 abstract description 42
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 47
- 201000010099 disease Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 241000700605 Viruses Species 0.000 description 27
- 230000004044 response Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000037452 priming Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 101710142585 50S ribosomal protein 6, chloroplastic Proteins 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002101 lytic effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 101150073066 F13L gene Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000011931 Nucleoproteins Human genes 0.000 description 5
- 108010061100 Nucleoproteins Proteins 0.000 description 5
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 description 5
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000000666 Fowlpox Diseases 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- -1 IFN-7 Proteins 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 241000700663 Avipoxvirus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000178270 Canarypox virus Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241001067453 Therion Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BMNBFRJBYVIOAY-UHFFFAOYSA-N 4,7,8-trihydroxy-3,4-dihydro-2h-isoquinolin-2-ium-1-one;chloride Chemical compound [Cl-].OC1=CC=C2C(O)C[NH2+]C(=O)C2=C1O BMNBFRJBYVIOAY-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 101150089247 B7 gene Proteins 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 101100004352 Escherichia coli lacZ gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- HDKLIZDXVUCLHQ-UHFFFAOYSA-N non-3-en-2-one Chemical compound CCCCCC=CC(C)=O HDKLIZDXVUCLHQ-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000013274 squamous cell breast carcinoma Diseases 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to the field of immunizations and the use of targeted immunotherapy to effect disease onset and/or disease progression.
- the present invention also relates to human cancer immunotherapy. BACKGROUND OF THE INVENTION
- Vaccines for cancer, infectious diseases (e.g., HIV) and autoimmune processes represent a major field of current research.
- the lack of effective vaccination schemes for these complex diseases represents a major obstacle in the generation of an antigen-specific immune response. Accordingly, effective schemes for administration of vaccine protocols are needed.
- the potential public health impact of the development of new vaccination schemes for cancer, infectious disease and autoimmune disease is enormous.
- Vaccinia viruses have been extensively used in humans as a vaccine and its use against smallpox has led to the worldwide eradication of this disease (Moss, B. Science 252:1662-1667, 1991) .
- Vaccina virus is a member of the pox virus family of cytoplasmic DNA viruses. DNA recombination occurs during replication of pox viruses and this has been used to insert DNA into the viral genome .
- Vaccinia viruses have the advantages of low cost, heat stability and a simple method of administration. Attempts have been made to develop vaccinia virus vectors for the prevention of other diseases.
- Cooney et al immunized 35 healthy HIV seronegative males with a recombinant vaccinia virus expressing the gpl60 envelope gene of HIV (Cooney, E.. The Lancet 337:567-572, 1991) .
- Graham et al randomized 36 volunteers to receive either recombinant vaccinia virus containing the gpl60 HIV envelope protein or control vaccinia virus (Graham, B.S. et al J. Infect. Pis. 166:244-252, 1992) .
- Fowlpox viruses are members of the pox virus family (avipox virus genus) and have also been utilized in the development of vaccines .
- Fowlpox virus only replicates in avian cells and cannot replicate in human cells. It is a cytoplasmic virus that does not integrate into the host genome but is capable of expression of a large number of recombinant genes in eukaryotic cells.
- Recombinant fowlpox virus expressing rabies glycoprotein has been used to protect mice, cats and dogs against live rabies virus challenge. Immunization of chickens and turkeys with a recombinant fowlpox expressing the influenza HA antigen protected against a lethal challenge with influenza virus (Taylor, J.
- Canarypox virus another member of the avipox genus similar to fowlpox, was safely administered subcutaneously to 25 normal human volunteers at doses up to IO 11 infectious doses (Cadox, M. et al The Lancet 339:1429-1432, 1992) .
- Fowlpox virus thus represents an attractive vehicle for immunization since it can stimulate both humoral and cellular immunity, it can be economically produced in high titers (10 9 pfu/ml) and yet its inability to productively infect human cells substantially increases the safety of its use, compared to replicating viruses such as vaccina virus, especially in immunocompromised hosts.
- fowlpox virus Another considerable advantage of fowlpox virus is that there is apparently little or no cross-reactivity with vaccinia virus and thus previously vaccinated humans will not have pre-existing immune reactivity to fowlpox virus proteins.
- TAA Tumor associated antigens
- TIL tumor infiltrating lymphocytes
- These vaccine strategies include immunization with unique TAA peptide epitopes mixed with adjuvants such as incomplete Freund's adjuvant ("IFA”) or bacillus calmette guerin (“BCG”) , intramuscular or "gene gun” immunization with plasmid DNA vaccines encoding the gene for a TAA, immunization with whole TAA protein vaccines, or immunization with recombinant viral or bacterial vaccines containing the gene for a TAA.
- adjuvants such as incomplete Freund's adjuvant (“IFA”) or bacillus calmette guerin (“BCG”)
- IFA incomplete Freund's adjuvant
- BCG bacillus calmette guerin
- IFA incomplete Freund's adjuvant
- BCG bacillus calmette guerin
- CTL cytotoxic T lymphocytes
- the present invention relates to methods for generating an antigen-specific immune response capable of preventing and/or treating disease. More specifically, the present invention relates to the use of priming and boosting with two different recombinant vectors (heterologous boosting) for the generation of CTL. The present invention relates to the use of multiple different DNA vectors carrying genes encoding one or more antigens for generating a strong cytotoxic T lymphocyte response to said antigen. The use of different vectors and the same antigen gene(s) for immunization and boosting phases of vaccination provides a novel method for eradication of disease.
- TAAs tumor associated antigens
- the present invention also relates to human cancer immunotherapy and the use of heterologous immunizations for treatment of cancers in humans.
- the immunotherapy methods of the present invention relates to the use of at least two different recombinant vectors expressing the same tumor-associated antigen for immunizing and boosting vaccinations for active treatment of malignant disease.
- the method mediates powerful CTL responses and anti-tumor immunity.
- Fig. 1. Shows prolonged survival of tumor-bearing animals after immunizing and boosting with different recombinant vectors.
- Fig. 2 In vivo, secondary CTL responses in mice immunized with different homologous and heterologous vaccination regimes.
- CT26. T (3-gal-,0) and CT26.CL25 ( ⁇ - gal+, •) served as targets.
- E:T Ratio represents the Effector to Target ratio. Experiment was repeated seven times with identical results.
- Fig. 3A and Fig.3B Naive BALB/c mice were vaccinated with either no immunogen (None) , 10 ⁇ g of /3-gal DNA intradermally with the gene gun (DNA) , 10 7 PFU of rW expressing /3-gal (VJS6) intravenously, or IO 7 PFU or rFPV.bg40k (FPV) intravenously. Twenty-one days later, each group of mice (two/group) was boosted with the same amount of each immunogen to compare all heterologous and homologous immunization regimens. On the day of the boost and eight days following the boost, sera was harvested and assayed for antibody reactivity in ELISA against /3-gal protein (Fig. 3A) .
- Fig. 4 Western Blot of purified /3-gal protein, W-WT, FPV-WT using serum samples from mice immunized with VJS6, FPV.bg40 and pCMV//3-gal DNA.
- mice were immunized one time with either 10 ⁇ g of /3-gal DNA intradermally with the gene gun (left panel), IO 7 PFU or rW (VJS6) intravenously (middle panel) , or IO 7 PFU of rFPV.bg40k intravenously (right panel) .
- Twenty-one days later serum was harvested and tested by Western blots at a 1:200 dilution against nitrocellulose blots of 5 ⁇ g of /3-gal protein (Lanes 2, 5, and 8), 6.6 x IO 6 PFU of W-WT (Lanes 3, 6, and 9) , or 2 x 10 7 PFU of FPV-WT (Lanes 4, 7, and 10) .
- the present invention relates to methods of vaccination for the effective generation of an antigen- specific immune response.
- the present invention relates to therapeutic methods of immunotherapy for treatment of disease and thus, prolonged survival in diseased patients.
- the present invention relates to heterologous boosting immunizations for the generation of Cytotoxic T Lymphocytes ("CTL”) .
- CTL Cytotoxic T Lymphocytes
- the present invention also relates to heterologous boosting immunizations for human cancer immunotherapy for the treatment of cancer patients.
- the present invention provides a method for inducing an immunological response in a mammal comprising a first step of inoculating the mammal with a recombinant vaccination vector and a second step of inoculating the mammal with a boosting immunization comprising a second recombinant vaccination vector different from the vector administered in the first step.
- the vaccination vectors of the present invention comprise viral vectors or plasmid DNAs and one or more genes encoding antigens specifically associated with a particular disease state. Although different vaccination vectors are utilized in step one and step two of the method both vaccination vectors encode at least one common antigen.
- Any recombinant vector may be utilized in the present invention, as many are known in the art (Baxby et al. Vaccine, 10:8-9, 1992; Moss et al . Science, 252:1662- 1667, 1991; Irvine et al. , Se . Cane . Biol . , 6:337-347, 1995.
- the vector to be used is preferably one that does not integrate with the host organism but effectively expresses the heterologous genes carried on the vector.
- Recombinant viral vectors used in the present invention are preferably one that does not integrate with the host organism but effectively expresses the heterologous genes carried on the vector.
- the recombinant vector has incorporated into its genome a gene encoding an antigen associated with a disease.
- the recombinant vector may also have one or more genes encoding one or more immunostimulatory molecules.
- a host cell infected with the recombinant vector expresses both the antigen(s) associated with a disease and may optionally also express immunostimulatory molecule (s) . Both the antigen and the immunostimulatory molecule may be expressed at the cell surface or may be actively secreted by the host cell.
- the priming dose of an antigen results in the activation and expansion of clonotypes capable of recognizing a particular peptide antigen presented in the context of its restricting MHC molecule.
- Boosting immunization of the present invention using a different vector than the priming dose leads to strong expansion of the secondary CD8+ T cell population specific for the heterologous antigen.
- the up-regulation of the immune response leads to an increase in antigen- specific cytotoxic lymphocytes which are able to kill or inhibit the growth of a disease-causing agent or a diseased cell.
- the present invention relates to a "boosting" vaccination strategy that elicits both an enhanced antigen specific CTL and antibody response, while at the same time generating a more therapeutic antigen response.
- Boosting with a different vector strongly enhances the ability of the recipient mammal to generate antigen specific CTL and antibody responses, thereby leading to the elicitation of a therapeutic response.
- a recombinant vector comprising more than one antigen of interest for the purpose of having a multivalent vaccine.
- the recombinant vector of the present invention comprises one or more nucleic acid sequences encoding one or more antigens or immunodominant epitopes of the antigens.
- one or more nucleic acid sequences encoding one or more immunostimulatory molecules may also be carried on the recombinant vector for the purpose of enhancing immune response against the antigen associated with the disease.
- the recombinant vector may comprise a viral genome or portions thereof, and the nucleic acid sequence encoding an antigen such as, for example, GP120 (from HIV) , MART-1, MAGE-1 or Hep B surface antigen.
- an antigen such as, for example, GP120 (from HIV) , MART-1, MAGE-1 or Hep B surface antigen.
- the treatment of cancer is addressed.
- the recombinant vectors used express one or more tumor antigens.
- genes encoding cytokines (TNF- ⁇ , IFN-7, GM-CSF, IL-10 and IL-2) , restriction elements (class 1 ⁇ -chains and j3 2 m) , and co-stimulatory and accessory molecules (B7-1, B7-2 and ICAM-1 and the like) alone and in a variety of combinations may also be included in the vaccination vector.
- Simultaneous production of an immunostimulatory molecule and one or more TAAs at the site of virus replication/infection enhances the generation of specific effector molecules, thereby enhancing the therapeutic effect of the present invention.
- the insertion of costimulatory molecules and/or cytokine genes may also be beneficial in treatment of established metastases .
- Viral vectors may be used as recombinant vectors in the present invention, wherein a portion of the viral genome is deleted to introduce new genes without destroying infectivity of the virus.
- the viral vector of the present invention is a nonpathogenic virus.
- the viral vector has a tropism for a specific cell type in the mammal.
- the viral vector of the present invention is able to infect professional antigen presenting cells such as dendritic cells and macrophages.
- the viral vector is able to infect any cell in the mammal.
- the viral vector may also infect tumor cells.
- Viral vectors used in the present invention include but is not limited to Poxvirus such as vaccinia virus, avipox virus, fowlpox virus and a highly attenuated vaccinia virus (Ankara or MVA) , retrovirus, adenovirus, baculovirus and the like.
- Poxvirus such as vaccinia virus, avipox virus, fowlpox virus and a highly attenuated vaccinia virus (Ankara or MVA) , retrovirus, adenovirus, baculovirus and the like.
- Expression vectors suitable for use in the present invention comprise at least one expression control element operationally linked to the nucleic acid sequence.
- the expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence.
- Examples of expression control elements are well known in the art (Ausubel et al. , (1987) in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York) and include, for example, the lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus or SV40.
- Additional preferred or required operational elements include, but are not limited to, leader sequence, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector should contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods (Ausubel et al . , (1987) in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York) or commercially available.
- the vaccinia virus genome is known in the art and it is composed of a Hind F13L region, TK region, and an HA region.
- the recombinant vaccinia virus has been used in the art to incorporate an exogenous gene for expression of the exogenous gene product (Perkus et al . Science 229:981-984, 1985; Kaufman et al . Int . J. Cancer 48:900-907, 1991; Moss Science 252:1662, 1991) .
- a general strategy for construction of vaccinia virus expression vectors is known in the art (Smith and Moss Bio Techniques Nov/Dec, p. 306-312, 1984; U.S. Patent No. 4,738,846) .
- a gene encoding an antigen associated with a disease may be incorporated into the Hind F13L region, or alternatively, incorporated into the TK region of recombinant vaccinia virus vector.
- a gene encoding an immunostimulatory molecule may be incorporated into the Hind F13L region or the TK region of recombinant vaccinia virus vector.
- the method of the present invention is effective in treating or preventing disease.
- Many diseases have specific antigens associated with the disease state.
- Such antigens or immunodominant epitopes of these antigens are crucial to immune recognition and ultimate elimination or control of the disease in a patient.
- Such antigens are referred to in the art as protective antigens.
- the method of the present invention may be used to treat any disease wherein a specific antigen or group of antigens is associated with the disease state.
- the immunotherapy method of the present invention may be used to treat diseases, for example, human acquired immune deficiency syndrome, HIV, bacterial infections, viral infections, autoimmune diseases and cancers.
- diseases for example, human acquired immune deficiency syndrome, HIV, bacterial infections, viral infections, autoimmune diseases and cancers.
- Specific examples of cancer types include but are not limited to melanoma, metastases, adenocarcinoma, thyoma, lymphoma, sarcoma, lung cancer, liver cancer, colon cancer, non-
- melanoma includes, but is not limited to, melanomas, metastatic melanomas, melanomas derived from either melanocytes or melanocytes related nevus cells, melanocarcinomas, melanoepithelio as, melanosarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, invasive melanoma or familial atypical mole and melanoma (FAM-M) syndrome.
- melanomas metastatic melanomas, melanomas derived from either melanocytes or melanocytes related nevus cells
- melanocarcinomas melanoepithelio as, melanosarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma,
- Such melanomas in mammals may be caused by, chromosomal abnormalities, degenerative growth and developmental disorders, mitogenic agents, ultraviolet radiation (UV) , viral infections, inappropriate tissue expression of a gene, alterations in expression of a gene, and presentation on a cell, or carcinogenic agents.
- the aforementioned cancers can be assessed or treated by methods of the present invention.
- a gene encoding an antigen associated with the cancer is incorporated into the recombinant virus genome or portion thereof along with a gene encoding one or more immunostimulatory molecules.
- the antigen associated with the cancer may be expressed on the surface of a cancer cell, may be secreted or may be an internal antigen.
- the antigen associated with the cancer is a tumor associated antigen (TAA) or portion thereof.
- TAA tumor associated antigen
- examples of TAA that may be used in the present invention include but are not limited to melanoma TAAs which include but are not limited to MART-1 (Kawakami et al . J. Exp.
- MAGE-3 is expressed on many tumors of several types, such as melanoma, head and neck squamous cell carcinomas, lung carcinoma and breast carcinoma but not in normal tissues except for testes.
- the approximately 1.6 Kilobase (kb) cDNA of MART-1 was cloned into a vector and the resulting plasmid, deposited with the American Type Culture Collection (ATCC Deposit Number 75738) .
- the cloning of MART-1 is disclosed in Kawakami et al . (J. Exp. Med. 180:347-352, 1994) and U.S. Patent Application Serial No. 08/231,565 (filed April 22, 1994) .
- the TAA may be CA-19-A (pancreatic cancer) , CA-125 (ovarian cancer) , PSA (prostate cancer) , erb-2 (breast cancer, CA-171A) and the like (Boon et al . Ann. Rev. Immunol 12:337, 1994) .
- the present invention is in no way limited to the genes encoding the above listed TAAs.
- Other TAAs are known to the skilled artisan and may be readily prepared by known methods, such as those disclosed in U.S. Patent No. 4,514,506.
- Genes encoding an antigen associated with a disease wherein the disease is caused by a pathogenic microorganism include viruses, bacteria and protozoans.
- viral agents examples include HIV (GP-120, pl7, GP-160 antigens) , influenza (NP, HA antigen) , herpes simplex (HSVdD antigen) , human papilloma virus, equine encephalitis virus, hepatitis (Hep B Surface Antigen) feline leukemia virus, canine distemper, rabies virus, and the like.
- Pathogenic bacteria include but are not limited to Chlamydia, Mycobacteria, Legioniella and the like.
- Pathogenic protozoans include but are not limited to malaria, Babesia, Schistosoma, Toxiplasma, Toxocara canis, and the like.
- Pathogenic yeast include Aspergillus, invasive Candida, and the like.
- Costimulation/Accessory Molecules and Cytokines A gene encoding one or more costimulation/accessory molecules and/or genes encoding an a cytokine may also be incorporated into the genome of a recombinant vaccination vector for use in the method of the present invention. Examples of costimulation molecules include but are not limited to B7-1, B7-2, ICAM- 1, ICAM-2, LFA-1, LFA-3, CD72 and the like.
- cytokines encompassed by the present invention include but are not limited to IL-2, IL-1, IL-3 through IL-9, IL-11, IL-13 through IL-15, G-CSF, M-CSF, GM-CSF, TNF ⁇ , IFN ⁇ , IFN ⁇ , IL-10, IL-12, regulated upon activation, normal T expressed and presumably secreted cytokine (RANTES) , and the like.
- chemokines encompassed by the present invention include but are not limited to CTAP III, ENA-78, GRO, 1-309, PF-4, IP-10, LD-78, MBSA, MlP-l ⁇ , MIP- IB and the like.
- the IFN ⁇ construct, TNF ⁇ construct, GM-CSF construct and ICAM-1 construct are described in Davidson et al (Nucleic Acid Research 18 (No. 14) :4285-4286, 1991) .
- the IL-2 gene of the present invention was made as disclosed by Taniguchi et al (Nature 302:305, 1983) . In one embodiment the entire IL-2 gene as disclosed in
- Taniguchi et al is incorporated into the TK gene sequence of vaccinia virus.
- the promotor sequence for the IL-2 construct of the present invention is made up of the P synthetic late promotor as disclosed in Davidson et al ( Nucleic Acid Research 18 (14:4285-4286, 1991) .
- the chimeric genes are then incorporated into the pox virus genome by homologous recombination in cells that have transfected with a plasmid vector containing the chimeric gene and infected with the pox virus.
- Co-stimulatory molecules of the B7 family represent a more recently discovered, but important group of molecules.
- B7.1 and B7.2 are both member of the Ig gene superfamily. These molecules are present on macrophages, dendritic cells, monocytes, i.e., antigen presenting cells (APCs) . If a lymphocyte encounters an antigen alone, with co- stimulation by B7.1, it will respond with either anergy, or apoptosis (programmed cell death) ; if the co- stimulatory signal is provided it will respond with clonal expansion against the target antigen.
- APCs antigen presenting cells
- the B7.1 gene may be inserted into the Hind F13L region of the vaccinia virus, with the /3-gal placed in the TK region.
- the construct for B7.2 and B7.1/B7.2 in conjunction with a tumor antigen are prepared in the same fashion as B7.1.
- the B7 gene is inserted into the TK region of vaccinia virus and the gene encoding /3-gal inserted in the Hind F13L region of the vaccinia virus.
- the present invention also encompasses methods of treatment or prevention of a disease.
- the administration of the recombinant vectors of the invention may be for either "prophylactic" or
- the recombinant vector of the present invention is provided in advance of any symptom.
- the prophylactic administration of the recombinant virus serves to prevent or ameliorate any subsequent infection or disease.
- the recombinant virus is provided at (or after) the onset of a symptom of infection or disease.
- the present invention may be provided either prior to the anticipated exposure to a disease- causing agent or after the initiation and/or progression of the infection or disease.
- tumor-specific antigens allows for the development of targeted antigen-specific vaccines for cancer therapy.
- Insertion of a tumor antigen gene in the genome of multiple different viral vectors provides a powerful system to elicit specific immune response for prevention in patients with an increased risk of cancer development (preventive immunization) , prevention of disease recurrence after primary surgery (anti-metastatic vaccination) , or as a tool to expand the number of CTL in vivo, thus improving their effectiveness in eradication of diffuse tumors (treatment of established disease) .
- the method of the present invention may elicit an immune response in a patient that is enhanced ex vivo prior to being transferred back to the tumor bearer (adoptive immunotherapy) .
- unit dose refers to physically discrete units suitable as unitary dosages for mammals, each unit containing a predetermined quantity of recombinant virus calculated to produce the desired immunogenic effect in association with the required diluent.
- a unit dose of a viral vector will vary depending upon the virus selected for use. Generally, a unit dose comprises a viral titer in the range of 10 6 -10 10 plaque forming units (PFU) . When other DNA vectors are used, 1-1000 ⁇ g is the preferred range for a unit dose.
- the unit dose may be the same for priming and boosting immunizations or it may be desired to alter the quantity of recombinant vector provided in the boosting phase as compared to the initial priming dose.
- the unit dose of an inoculum of this invention is dictated by and dependent upon the unique characteristics of the recombinant vectors and the particular immunologic effect to be achieved, as is well-recognized by the skilled artisan.
- the dosage of administered recombinant vectors will vary depending upon such factors as the mammal's age, weight, height, sex, general medical condition, previous medical history, disease progression, tumor burden and the like.
- the inoculum is typically prepared as a solution in tolerable (acceptable) diluent such as saline, phosphate-buffered saline or other physiologically tolerable diluent and the like to form an aqueous pharmaceutical composition.
- Adjuvants known in the art are also suitable for the preparation of a unit dose.
- the route of inoculation may be intravenous (I.V.) , intramuscular (I.M.) , subcutaneous (S.C.) , intradermal (I.D.) intraperitoneal (I.P.) and the like, which results in eliciting a protective response against the disease causing agent.
- a priming dose is administered at least once, and may be provided in multiple doses.
- Boosting doses comprising a different vector encoding the same antigen as the priming dose follow and may be administered in one or more unit doses.
- the recombinant vector can be introduced into a mammal either prior to any evidence of cancers such as melanoma or to mediate regression of the disease in a mammal afflicted with a cancer such as melanoma.
- methods for administering the vector into mammals include, but are not limited to, exposure of cells to the recombinant virus ex vivo, or injection of the recombinant vector into the affected tissue or intravenous S.C., I.D., I.P. or I.M. administration of the vector.
- the recombinant vector or combination of recombinant vectors may be administered locally by direct injection into the cancerous lesion or topical application in a pharmaceutically acceptable carrier.
- the quantity of recombinant viral vector, carrying the nucleic acid sequence of one or more TAAs to be administered is based on the titer of virus particles.
- a preferred range of the immunogen to be administered is 10 5 to 10 10 PFU per dose, preferably in a human.
- the efficacy of the vaccine can be assessed by production of antibodies or immune cells that recognize the antigen, as assessed by specific lytic activity or specific cytokine production or by tumor regression.
- One skilled in the art recognizes the conventional methods to assess the aforementioned parameters. If the mammal to be immunized is already afflicted with cancer or metastatic cancer, the vaccine may be administered in conjunction with other therapeutic treatments.
- autologous cytotoxic lymphocytes or tumor infiltrating lymphocytes may be removed from the patient with cancer as disclosed in U.S. Patent No. 5,126,132 and U.S. Patent No. 4,690,915.
- the lymphocytes are grown in culture and antigen specific lymphocytes expanded by culturing in the presence of the recombinant vectors of the present invention.
- the antigen specific lymphocytes are then reinfused back into the patient.
- the present invention also encompasses combination immunotherapy.
- combination therapy is meant that the recombinant vector containing one or more genes encoding one or more antigens associated with one or more disease agents and, optionally, one or more genes encoding immunostimulatory molecules is administered to the patient in combination with other exogenous immunomodulators or immunostimulatory molecules, chemotherapeutic drugs, antibiotics, antifungal drugs, antiviral drugs and the like alone or in combination thereof.
- exogenously added agents examples include exogenous IL-2, IL-6, IL-10, IL-12, GM-CSF, interferon, IL-10, tumor necrosis factor, RANTES (Promega, G5661) , cyclophosphamide, and cisplatin, gancyclovir, amphotericin B and the like.
- the present invention establishes that a boosting vaccination with a different vaccine vector ("heterologous boosting") expressing a TAA rather than the same vaccine vector (“homologous boosting”) elicits a more potent TAA-specific primary CTL response. Similar responses were seen in two separate model TAA system, i.e., jS-galactosidase, and influenza (A/PR/8/34) nucleoprotein (NP) .
- heterologous boosting expressing a TAA rather than the same vaccine vector
- NP nucleoprotein
- the present invention demonstrates that the generation of an antibody and a primary TAA-specific CTL response following vaccination with plasmid DNA encoding a model TAA is enhanced by a boosting vaccination with either rFPV or rW expressing the TAA, but not with a boosting vaccination of the same DNA plasmid vector.
- the present invention also found that the generation of a primary TAA-specific CTL response following vaccination with a rW expressing a model TAA is enhanced by a boosting vaccination with a rFPV expressing the TAA, but not with a boosting vaccination of the same rW vector.
- Antibody responses can be enhanced with both homologous and heterologous vectors.
- the generation of a primary TAA- specific CTL response following vaccination with a rFPV expressing a model TAA is enhanced by a boosting vaccination with a rW expressing the TAA, but not with a boosting vaccination of same rFPV vector.
- Antibody responses are enhanced with both homologous and heterologous vectors .
- the generation of a primary TAA- specific CTL response following vaccination with rAdeno expressing a model TAA can be enhanced by a boosting vaccination with either a rW or rFPV expressing the TAA, but not with a boosting vaccination with the same rAdeno vector.
- the present invention also demonstrates that boosting responses which elicit enhanced CTL responses correlate with prolonged survival in tumor-bearing animals.
- CT26.WT is a clone of the N-nitroso-N-methylurethrane induced BALB/c (H-2 d ) undifferentiated colon carcinoma. Following transduction with a retrovirus encoding the lacZ gene. CT26.WT was subcloned to generate the /3-gal expressing cell line CT26.CL25 (Wang et al. J. Immunol . 154 (9) :4685-4692, 1995) .
- Plasmid preparations and Gene Gun Delivery of DNA A plasmid encoding the Escherichia coli lacZ gene (pCMV//3- gal) under the control of the human CMV intermediate-early promotor, designated pCMV//3-gal was kindly provided by J. Haynes (Agracetus, Middleton, WI) .
- a plasmid expressing the nucleoprotein from influenza A virus (A/PR/8/34) also under the control of the CMV promotor was used as a control vector in this study. Closed circular plasmid DNA was isolated using Wizard maxipreps DNA purification kits (Promega Corp, Madison, WI) .
- Plasmid DNA and gold were coprecipitated by the addition of 200 ⁇ l of 2.5 M Cacl 2 during vortex mixing as previously described (Fuller et al., AIDS Res . Hum. Retrovir, 10(11) :1433, 1994) .
- DNA- coated gold particles were delivered into abdominal epidermis using the hand-held helium driven device Accell ® gene delivery system (kindly provided by Geniva, Middleton, WI) . Each animal received 10 non-overlapping deliveries per immunization at a pressure of 400 psi of helium.
- Recombinant viruses The recombinant vaccinia virus (rW) vaccine, VJS6, was engineered such that the E.
- coli lacZ gene encoding 0-gal was under the control of the early/late W 7.5K promoter from plasmid pSC65 (Bronte et al. J. Immunol . , 154 (10) :5282-5292, 1995) .
- the rW, V69 was similarly constructed such that the gene encoding for nucleoprotein from influenza A (A/PR/8/34) was under the control of the early/late 7.5K promoter from plasmid PSC65 (V69) (Smith et al . , Virology, 160:336-345, 1987) .
- the recombinant stocks were initially propagated in the BSC-1 monkey kidney cell line to create a crude lysate which was then further purified over a sucrose cushion.
- the recombinant fowlpox viral (rFPV) vaccine used in these studies contains the E. coli lacZ gene under control of the vaccinia virus 40K promoter inserted into the BamHI region of the FPV genome as previously described (Therion Biologies Corp., Cambridge, MA) (Wang et al . , J. Immunol . , 154 (9) :4685-4692, 1995) .
- Fig. 1 BALB/c mice were challenged intravenously with 10 5 CT26.CL25 tumor cells to establish pulmonary metastases (Rao et al . J. Immunol . , 156:3357-3365, 1996) . Three days later, groups of mice (ten/group) were primed with either (Fig. 1, Panel A) no immunogen (None) (Fig. 1, Panel B) IO 7 PFU of rW expressing 3-gal (VJS6) intravenously, (Fig. 1, Panel A) no immunogen (None) (Fig. 1, Panel B) IO 7 PFU of rW expressing 3-gal (VJS6) intravenously, (Fig.
- mice were administered either no treatment, VJS6, rFPV.bg40 of pCMV//3-gal three days after tumor inoculation and then boosted with pCMV//3-gal DNA fourteen days later.
- the no treatment group (None-None) is shown in all graphs of Fig. 1 as a control group.
- Figure 1 represents data from one experiment performed identically two times with similar results.
- VJS6 rFPV expressing /3-gal
- FPV.bg40 rFPV expressing /3-gal
- mice were immunized with the different heterologous and homologous combinations of the pCMV//3-gal, VJS6 and rFPV.bg40 vaccines.
- mice were vaccinated with either no immunogen, 10 ⁇ g of /3-gal DNA intradermally with the gene gun, 10 7 PFU of rW (VJS6 or V69) intravenously, or IO 7 PFU of FPV.bg40k intravenously. Twenty-one days later, each group of mice was boosted with the same amount of each immunogen to compare all heterologous and homologous possibilities. To determine the optimal kinetics of an in vivo secondary CTL response, mice were sacrificed 2, 4, 6, and 8 days after the second vaccination at which time their spleens were removed and CTL lytic reactivity against /3-gal without an in vi tro stimulation step was assessed in a standard 6-hour 51 Cr release assay.
- mice were sacrificed at the optimal time-point, 4 days following the second vaccination and in vivo CTL lytic reactivity was assessed. Pooled serum (2 mice/group) was also taken eight days following the boost to evaluate antibody reactivity of /3-gal protein via an ELISA.
- 51 Cr release assay Six-hour 51 Cr release assays were performed as previously described (Restifo et al . , J. Exp . Mod . , 177:265-272, 1993) . Briefly, 2 x IO 6 target cells were incubated on 0.2 ml of CM labeled with 200 ⁇ Ci of Na 51 Cr0 4 for 90 min. Peptide-pulsed CT26.WT were incubated with l ⁇ g/ l (approximately 1 ⁇ M) antigenic peptide during labeling. Target cells were then mixed with effector cells for 6 h at 37°C at the effector to target ratios indicated. The amount of 51 Cr released was determined by gamma counting and the percentage of specific lysis was calculated as follows:
- % specific lysis [ (experimental cpm - spontaneous cpm) / (maximal cpm - spontaneous cpm)] x 100.
- Mice primed with either VJS6 or rFPV.bg40 and tested twenty-one days later did not elicit /3-gal-specific CTL. No CTL activity was observed when mice were immunized and boosted with the same vector, either VJS6 or rFPV.bg40 (Fig. 2) .
- boosting the VJS6-primed mice with a different vector, rFPV.bg40, induced antigen-specific CTL (Fig. 2) .
- Mice primed and boosted with rFPV.bg40 also did not induce anti-/3-gal CTL.
- rFPV.bg40-primed mice boosted with the heterologous vector, VJS6, elicited antigen-specific CTL (Fig. 2) .
- Mice primed with pCMV//3-gal DNA induced /3-gal- specific CTL only when boosted with either VJS6 or rFPV.bg40 (Fig. 2) .
- Enzyme-linked immunosorbent assay Serum from immunized mice was collected twenty-one days following the primary immunization and eight days following the final boost to be analyzed for the presence of antibodies against 3-gal, wild-type vaccinia virus or wild-type fowlpox virus by ELISA, as previously described (Irvine et al. J " . Immunol . , 256:238-245, 1996) . Specifically, microtiter plates were either dried down overnight at 37°C in a nonhumidified incubator with 200ng/well/50 ⁇ l of purified /3-gal protein (Sigma Chemical Co., St. Louis, MO) .
- microtiter plates were coated with either WT-W (5 x 10 5 / well/50 ⁇ l) or WT-FPV (5 x 10 5 / ell/50 ⁇ l) at 4°C overnight. Incubation of 5% BSA in PBS on each well for l-h to prevent nonspecific Ab binding was followed by a second l-h incubation with 50 ⁇ l of fivefold dilutions (starting at 1:100) of test sera.
- /3-gal-specific antibody titers were increased following a primary immunization with VJS6 with boosts of either pCMV/jS-gal, VJS6, or rFPV (Titers increased from 1:50 with no boost to 1:250 for each group, Fig. 3A) .
- /3-gal-specific antibody titers were also boosted when either pCMV//3-gal, VJS6, or rFPV were administered as a boost following pCMV//3-gal priming; -27 - these ranged from 1:200 to 1:2,500 for each (Fig. 3A) .
- CTL activity an enhancement of the anti-/3-gal antibody response was observed regardless of boosting with either a homologous vector or a heterologous vector expressing the same TAA.
- Vector-specific, high-titered antibodies were induced following a single immunization of either rW or rFPV.
- the blots were then incubated in PBS containing 5% nonfat dry milk for lh at RT. Ten ml of a 1:200 dilution of antiserum in PBS with 2% nonfat dry milk were added to each nitrocellulose strip and incubated for 2 h at room temperature with gentle agitation. After washing the blots with PBS containing 0.5% Tween-20, the blots were incubated with horseradish peroxidase- conjugated sheep anti-mouse IgG F(ab') 2 fragments (1:1000) (Amersham International, Amersham, UK) to visualize antibody binding.
- Bound immunoglobulin was then detected o by incubating the blots for approximately 3 minutes in 3, 3' -diaminabenzidine tetrahydrochloride (DAB, Sigma, St. Louis, MS) dissolved in dH 2 0. The reaction was stopped by washing for five minutes with dH 2 0.
- DAB 3, 3' -diaminabenzidine tetrahydrochloride
- the antibodies induced by immunization with pCMV//3-gal did not react with either VJS6 or rFPV.bg40 but did recognize 3-gal protein both by ELISA and by Western blot analysis (Fig. 3B & 4) .
- These data show that high titers of vector-specific antibodies were induced by immunization with either vaccinia virus or fowlpox viruses.
- the anti-vector antibodies may not only play a role in the lack of /3-gal specific CTL responses in groups of mice immunized and boosted with the same viral vector (Fig. 2) but may also reduce prolongation of survival in the groups of mice immunized and boosted with the same viral vectors (Fig. 1) .
- this strategy of immunizing and boosting with alternating recombinant vectors may be a more potent means of enhancing an immune response against a desired antigen than repetitive immunizations with the same vector.
- Melanoma patients are treated with viral vectors expressing TAAs.
- gmp quality recombinant viral and nonviral vectors expressing the TAAs human gplOO and MART-1 are produced.
- rFPV and rW that express each of the two aforementioned antigens have been produced (Therion, Inc.) .
- Recombinant adenoviruses expressing TAA are produced (Genzyme, Inc.) .
- recombinant DNA vectors and Influenza virus vectors expressing gplOO and peptide fragments of gplOO respectively are produced.
- Patients receive either rDNA at 2-8 ⁇ g per individual dose, Influenza virus vector or adenovirus (10 6 -10 n pfu/individual) .
- Three to six weeks later patients are boosted heterologously with 10 6 -10 n pfu per individual of either rFPV or rW.
- CTL and clinical responses are monitored in these patients.
- the clinical status of the tumors is evaluated at monthly intervals.
- melanoma patients received rW or rFPV every three weeks at dose ranging from 10 6 -10 9 .
- Antibody titers against the viral sectors have been measured from the sera of these patients.
- These patients have received boosting immunizations with heterologous vectors. Patient CTL and clinical responses are being monitored.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26787/97A AU2678797A (en) | 1996-04-22 | 1997-04-21 | Heterologous boosting immunizations |
US11/007,115 US20050100558A1 (en) | 1996-04-22 | 2004-12-08 | Heterologous boosting immunizations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1589396P | 1996-04-22 | 1996-04-22 | |
US60/015,893 | 1996-04-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/838,987 Continuation US20010036928A1 (en) | 1996-04-22 | 2001-04-20 | Heterologous boosting immunizations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039771A1 true WO1997039771A1 (en) | 1997-10-30 |
Family
ID=21774220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/006632 WO1997039771A1 (en) | 1996-04-22 | 1997-04-21 | Heterologous boosting immunizations |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2678797A (en) |
CA (1) | CA2252406A1 (en) |
WO (1) | WO1997039771A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044410A2 (en) * | 1999-01-28 | 2000-08-03 | Stichting Biomedical Primate Research Centre | Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors |
US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
WO2003038057A3 (en) * | 2001-11-01 | 2003-07-17 | Genphar Inc | Genetic vaccine against human immunodeficiency virus |
EP1335023A2 (en) * | 1997-06-09 | 2003-08-13 | Oxxon Pharmaccines Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
US6787351B2 (en) | 1999-07-06 | 2004-09-07 | Merck & Co., Inc. | Adenovirus carrying gag gene HIV vaccine |
US7273605B2 (en) | 2001-11-30 | 2007-09-25 | Isis Innovation Limited | Vaccine |
EP1964573A2 (en) | 1999-10-22 | 2008-09-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
WO2008122817A2 (en) * | 2007-04-10 | 2008-10-16 | Isis Innovation | Immunogenic compositions |
US8282935B2 (en) | 2001-07-30 | 2012-10-09 | Isis Innovation Limited | Materials and methods relating to improved vaccination strategies |
-
1997
- 1997-04-21 WO PCT/US1997/006632 patent/WO1997039771A1/en active Application Filing
- 1997-04-21 CA CA002252406A patent/CA2252406A1/en not_active Abandoned
- 1997-04-21 AU AU26787/97A patent/AU2678797A/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
BRONTE V. ET AL.: "IL-2 enhances the function of recombinant Poxvirus-based vaccines in the treatment of established pulmonary metastases", THE JOURNAL OF IMMUNOLOGY, vol. 154, 1995, pages 5282 - 5292, XP000676342 * |
CADOZ M. ET AL.: "Immunization with Canarypox virus expressing rabies glycoprotein", THE LANCET, vol. 339, no. 8807, 13 June 1992 (1992-06-13), pages 1429 - 1432, XP002036181 * |
CARROLL M W ET AL: "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model.", VACCINE 15 (4). 1997. 387-394, XP002036183 * |
CHAMBERLAIN R.S. ET AL.: "Use of multiple vaccination vectors for the generation of CTL against a model tumor antigen", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (WASHINGTON APRIL 20-24, 1996), vol. 37, 1996, XP002036179 * |
CHEN, PAULINE W. ET AL: "Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen", J. IMMUNOL. (1996), 156(1), 224-31, 1996, XP000674674 * |
WANG W. ET AL.: "Active immunotherapy of cancer with a nonreplicating recombinant Fowlpox virus encoding a model tumor-associated antigen", THE JOURNAL OF IMMUNOLOGY, vol. 154, 1995, pages 4685 - 4692, XP000676343 * |
ZHAI Y ET AL: "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.", JOURNAL OF IMMUNOTHERAPY 20 (1). 1997. 15-25., XP002036182 * |
ZHAI Y. ET AL: "Antigen-Specific Tumor Vaccines", THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 2, 15 January 1996 (1996-01-15), pages 700 - 710, XP002036180 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1589108A2 (en) * | 1997-06-09 | 2005-10-26 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US7514087B2 (en) | 1997-06-09 | 2009-04-07 | Oxxon Therapeutics Limited | Methods and reagents for immunization which generate a CD8 T cell immune response |
EP1616954A2 (en) * | 1997-06-09 | 2006-01-18 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
EP1616954A3 (en) * | 1997-06-09 | 2006-03-22 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
EP1335023A2 (en) * | 1997-06-09 | 2003-08-13 | Oxxon Pharmaccines Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US6663871B1 (en) | 1997-06-09 | 2003-12-16 | Oxxon Pharmaccines Ltd. | Methods and reagents for vaccination which generate a CD8 T cell immune response |
EP2058399A1 (en) * | 1997-06-09 | 2009-05-13 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US7407661B2 (en) | 1997-06-09 | 2008-08-05 | Oxxon Therapeutics Limited | Methods and reagents that generate a CD8 T cell immune response |
EP1589108A3 (en) * | 1997-06-09 | 2006-03-22 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
EP1335023A3 (en) * | 1997-06-09 | 2005-08-24 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US6783762B1 (en) | 1999-01-28 | 2004-08-31 | Stichting Biomedical Primate Research Centre | Product and method for obtaining specific immunization with one or more antigens |
WO2000044410A3 (en) * | 1999-01-28 | 2000-12-07 | Stichting Biomedical Primate R | Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors |
WO2000044410A2 (en) * | 1999-01-28 | 2000-08-03 | Stichting Biomedical Primate Research Centre | Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors |
US6787351B2 (en) | 1999-07-06 | 2004-09-07 | Merck & Co., Inc. | Adenovirus carrying gag gene HIV vaccine |
EP1964573A2 (en) | 1999-10-22 | 2008-09-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
US8282935B2 (en) | 2001-07-30 | 2012-10-09 | Isis Innovation Limited | Materials and methods relating to improved vaccination strategies |
WO2003038057A3 (en) * | 2001-11-01 | 2003-07-17 | Genphar Inc | Genetic vaccine against human immunodeficiency virus |
US7273605B2 (en) | 2001-11-30 | 2007-09-25 | Isis Innovation Limited | Vaccine |
WO2008122817A2 (en) * | 2007-04-10 | 2008-10-16 | Isis Innovation | Immunogenic compositions |
WO2008122817A3 (en) * | 2007-04-10 | 2008-12-11 | Isis Innovation | Immunogenic compositions |
Also Published As
Publication number | Publication date |
---|---|
AU2678797A (en) | 1997-11-12 |
CA2252406A1 (en) | 1997-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2261989C (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
US7211432B2 (en) | Recombinant vector expressing multiple costimulatory molecules and uses thereof | |
JP3907698B2 (en) | A composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule | |
AU712714B2 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system | |
AU2001286109B2 (en) | Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen | |
JP4282095B2 (en) | Methods and reagents for vaccination generating CD8 T cell immune responses | |
AU774076B2 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
EP1808180A2 (en) | Modified GP 100 and uses thereof | |
AU2001268452A1 (en) | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses | |
EP1292694A2 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
WO2006061643A1 (en) | Method for vaccinating usign a prime-boost regime and hsv as a vector | |
Esteban et al. | Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens | |
WO1997039771A1 (en) | Heterologous boosting immunizations | |
US20010036928A1 (en) | Heterologous boosting immunizations | |
US20210260176A1 (en) | Methods and Compositions for Vaccinating Against Malaria | |
CA2261990A1 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
US8921534B2 (en) | Enhancement of the immune response using CD36-binding domain | |
AU767562B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES | |
AU2003266471A1 (en) | Recombinant pox virus for immunization against tumor-associated antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2252406 Country of ref document: CA Ref country code: CA Ref document number: 2252406 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97538239 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |